Published in J Biol Chem on January 06, 2010
Interaction of thrombin with sucrose octasulfate. Biochemistry (2011) 0.95
Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli. Anal Biochem (2010) 0.78
Fluorescent reporters of thrombin, heparin cofactor II, and heparin binding in a ternary complex. Anal Biochem (2011) 0.75
Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb (2003) 4.44
Global kinetic explorer: a new computer program for dynamic simulation and fitting of kinetic data. Anal Biochem (2008) 3.63
Human thrombins. Production, evaluation, and properties of alpha-thrombin. J Biol Chem (1977) 3.21
FitSpace explorer: an algorithm to evaluate multidimensional parameter space in fitting kinetic data. Anal Biochem (2008) 2.82
Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. J Mol Biol (1997) 2.75
The analysis of progress curves for enzyme-catalysed reactions by non-linear regression. Biochim Biophys Acta (1977) 2.58
Determination of the rate constant of enzyme modification by measuring the substrate reaction in the presence of the modifier. Biochemistry (1982) 2.51
Blood clotting in minimally altered whole blood. Blood (1996) 2.10
Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. Methods Enzymol (1981) 1.82
Thrombin. Mol Aspects Med (2008) 1.80
Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol (1993) 1.66
A player of many parts: the spotlight falls on thrombin's structure. Thromb Res (1993) 1.64
Exosites in the substrate specificity of blood coagulation reactions. J Thromb Haemost (2007) 1.61
Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin. Thromb Haemost (2004) 1.61
Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc Natl Acad Sci U S A (2002) 1.46
Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin. J Biol Chem (1998) 1.34
Activation of heparin cofactor II by dermatan sulfate. J Biol Chem (1983) 1.33
Mechanisms of action of sucralfate. J Clin Gastroenterol (1981) 1.28
Binding of substrate in two conformations to human prothrombinase drives consecutive cleavage at two sites in prothrombin. J Biol Chem (2004) 1.26
Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J Biol Chem (1990) 1.26
The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II. J Biol Chem (2003) 1.25
Exosite determinants of serpin specificity. J Biol Chem (2009) 1.23
Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. Linkage of protease-inhibitor-heparin interactions in the reaction with thrombin. J Biol Chem (1988) 1.20
Inactivation of thrombin by antithrombin is accompanied by inactivation of regulatory exosite I. J Biol Chem (1997) 1.20
Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest (2002) 1.18
Binding of exosite ligands to human thrombin. Re-evaluation of allosteric linkage between thrombin exosites I and II. J Biol Chem (2001) 1.17
Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci U S A (1989) 1.17
Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by a template mechanism. Evidence that calcium alleviates Gla domain antagonism of heparin binding to factor Xa. J Biol Chem (1998) 1.16
Multiple active forms of thrombin. IV. Relative activities of meizothrombins. J Biol Chem (1990) 1.13
Prothrombin. Methods Enzymol (1981) 1.13
Nematode anticoagulant protein c2 reveals a site on factor Xa that is important for macromolecular substrate binding to human prothrombinase. J Biol Chem (2002) 1.12
Na+ binding to meizothrombin desF1. Cell Mol Life Sci (2008) 1.10
Active-site-selective labeling of blood coagulation proteinases with fluorescence probes by the use of thioester peptide chloromethyl ketones. I. Specificity of thrombin labeling. J Biol Chem (1992) 1.06
The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. Biochemistry (1997) 1.03
Mechanism of acceleration of antithrombin-proteinase reactions by low affinity heparin. Role of the antithrombin binding pentasaccharide in heparin rate enhancement. J Biol Chem (1995) 1.02
Structural studies of the binding of the anti-ulcer drug sucrose octasulfate to acidic fibroblast growth factor. Structure (1993) 1.01
Expression of allosteric linkage between the sodium ion binding site and exosite I of thrombin during prothrombin activation. J Biol Chem (2007) 1.01
Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem (1986) 1.01
Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate. Mol Cell Biol (2002) 1.00
Role of regulatory exosite I in binding of thrombin to human factor V, factor Va, factor Va subunits, and activation fragments. J Biol Chem (1999) 1.00
Development of a calibrated automated thrombography based thrombin generation test in mouse plasma. J Thromb Haemost (2007) 0.97
The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans. J Biol Chem (1991) 0.95
Critical role of the linker region between helix D and strand 2A in heparin activation of antithrombin. J Biol Chem (2000) 0.94
The measurement and application of thrombin generation. Br J Haematol (2005) 0.94
Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes. J Biol Chem (1998) 0.93
Solution structure of the ligand binding domain of the fibroblast growth factor receptor: role of heparin in the activation of the receptor. Biochemistry (2005) 0.93
Crystal structures of the heparan sulfate-binding domain of follistatin. Insights into ligand binding. J Biol Chem (2003) 0.92
The heparin binding properties of heparin cofactor II suggest an antithrombin-like activation mechanism. J Biol Chem (2004) 0.90
Role of thrombin exosites in inhibition by heparin cofactor II. J Biol Chem (1992) 0.90
Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. Characterization of assembly, product formation, and heparin dissociation steps in the factor Xa reaction. J Biol Chem (1989) 0.90
Antithrombin activity of a peptide corresponding to residues 54-75 of heparin cofactor II. J Biol Chem (1989) 0.88
Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin. J Biol Chem (1989) 0.85
Glycosaminoglycan-mediated leuserpin-2/thrombin interaction. Structure-function relationships. J Biol Chem (1990) 0.85
Sucralfate and soluble sucrose octasulfate bind and stabilize acidic fibroblast growth factor. Biochim Biophys Acta (1993) 0.83
Inhibition of thrombin by sulfated polysaccharides isolated from green algae. Biochim Biophys Acta (2000) 0.82
Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. The reaction step limiting heparin turnover in thrombin neutralization. J Biol Chem (1986) 0.81
Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost (1998) 0.80
Aspartic acid residues 72 and 75 and tyrosine-sulfate 73 of heparin cofactor II promote intramolecular interactions during glycosaminoglycan binding and thrombin inhibition. J Biol Chem (2002) 0.80
Enhancement of heparin cofactor II anticoagulant activity. J Biol Chem (1999) 0.80
Insight into the mechanism of action of heparin cofactor II. Thromb Haemost (1995) 0.80
Amino acid residues of heparin cofactor II required for stimulation of thrombin inhibition by sulphated polyanions. Biochim Biophys Acta (1999) 0.79
Plasma levels of heparin cofactor II (HCII) and thrombin-HCII complex in patients with disseminated intravascular coagulation. Clin Appl Thromb Hemost (2002) 0.79
Anticoagulant and antithrombotic activity of maltodapoh, a novel sulfated tetrasaccharide. J Pharmacol Exp Ther (1999) 0.79
Sucrose octasulfate regulates fibroblast growth factor-2 binding, transport, and activity: potential for regulation of tumor growth. J Cell Physiol (2008) 0.78
Tyrosine sulfation and N-glycosylation of human heparin cofactor II from plasma and recombinant Chinese hamster ovary cells and their effects on heparin binding. Eur J Biochem (2002) 0.78
Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyelocytic leukemia. Thromb Res (1992) 0.78
Interaction of the sulfated lactobionic acid amide LW 10082 with thrombin and its endogenous inhibitors. Thromb Res (1991) 0.77
Structure-function relationships in heparin cofactor II: spectral analysis of aromatic residues and absence of a role for sulfhydryl groups in thrombin inhibition. Arch Biochem Biophys (1987) 0.77
Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides. Thromb Res (2001) 0.77
Influence of lactobionic acid on the kinetics of thrombin in human plasma. Semin Thromb Hemost (1991) 0.76
Tissue distribution of [14C]sucrose octasulfate following oral administration to rats. Pharm Res (2002) 0.76
Conformational analysis of sucrose octasulfate by high resolution nuclear magnetic resonance spectroscopy. Carbohydr Res (1995) 0.76
Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082. Eur J Biochem (1992) 0.76
Dimerization effect of sucrose octasulfate on rat FGF1. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 0.76
Antithrombotic and anticoagulant properties of synthetic polyanions: sulfated bis-aldonic acid amides. J Pharmacol Exp Ther (1991) 0.76
Biochemical studies on sulfated lactobionic acid amides. Semin Thromb Hemost (1991) 0.76
Pharmacologic profile of the antithrombotic and bleeding actions of sulfated lactobionic acid amides. Semin Thromb Hemost (1991) 0.75
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58
Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med (2005) 3.59
Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med (2006) 2.54
Factor XI contributes to thrombin generation in the absence of factor XII. Blood (2009) 2.31
Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension (2004) 2.18
Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood (2008) 1.89
A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood (2010) 1.83
Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood (2014) 1.81
Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). Arterioscler Thromb Vasc Biol (2009) 1.64
Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol (2004) 1.44
Structure and function of factor XI. Blood (2010) 1.37
Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol (2013) 1.30
Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood (2011) 1.22
The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa. J Biol Chem (2002) 1.13
Identification of a binding site for glycoprotein Ibalpha in the Apple 3 domain of factor XI. J Biol Chem (2004) 1.10
Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein. J Biol Chem (2001) 1.07
Contributions of basic amino acids in the autolysis loop of factor XIa to serpin specificity. Biochemistry (2006) 1.05
Factor XI and XII as antithrombotic targets. Curr Opin Hematol (2011) 1.02
Characterization of Novel Forms of Coagulation Factor XIa: independence of factor XIa subunits in factor IX activation. J Biol Chem (2008) 1.02
The intrinsic pathway of coagulation is essential for thrombus stability in mice. Blood Cells Mol Dis (2006) 1.02
Role of Factor XII in hemostasis and thrombosis: clinical implications. Expert Rev Cardiovasc Ther (2007) 1.00
Activation of factor XI by products of prothrombin activation. Blood (2011) 0.99
Factor V Leiden protects against blood loss and transfusion after cardiac surgery. Circulation (2003) 0.97
Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa. J Med Chem (2013) 0.97
Resolution of conformational activation in the kinetic mechanism of plasminogen activation by streptokinase. J Biol Chem (2004) 0.97
Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor. Biochemistry (2009) 0.96
Exosite-mediated substrate recognition of factor IX by factor XIa. The factor XIa heavy chain is required for initial recognition of factor IX. J Biol Chem (2005) 0.95
Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis. J Infect Dis (2008) 0.95
Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets. Mol Pharmacol (2013) 0.93
Activated factor XI inhibits chemotaxis of polymorphonuclear leukocytes. J Leukoc Biol (2011) 0.93
Update on the physiology and pathology of factor IX activation by factor XIa. Expert Rev Hematol (2008) 0.93
A sequential mechanism for exosite-mediated factor IX activation by factor XIa. J Biol Chem (2012) 0.93
Cloning and characterization of the human factor XI gene promoter: transcription factor hepatocyte nuclear factor 4alpha (HNF-4alpha ) is required for hepatocyte-specific expression of factor XI. J Biol Chem (2002) 0.92
The dimeric structure of factor XI and zymogen activation. Blood (2013) 0.92
Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Blood (2012) 0.91
Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood (2004) 0.91
Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site. J Med Chem (2013) 0.90
Binding of the COOH-terminal lysine residue of streptokinase to plasmin(ogen) kringles enhances formation of the streptokinase.plasmin(ogen) catalytic complexes. J Biol Chem (2006) 0.90
Molecular cloning and biochemical characterization of rabbit factor XI. Biochem J (2002) 0.89
Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice. Transl Stroke Res (2012) 0.88
Role of the streptokinase alpha-domain in the interactions of streptokinase with plasminogen and plasmin. J Biol Chem (2004) 0.85
Structural role of Gly(193) in serine proteases: investigations of a G555E (GLY193 in chymotrypsin) mutant of blood coagulation factor XI. J Biol Chem (2004) 0.85
Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition. Protein Sci (2011) 0.84
Fibrin facilitates both innate and T cell-mediated defense against Yersinia pestis. J Immunol (2013) 0.83
Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis. Infect Immun (2011) 0.81
Differential role of the carboxy-terminus of the A(2B) adenosine receptor in stimulation of adenylate cyclase, phospholipase Cbeta, and interleukin-8. Purinergic Signal (2009) 0.81
A classification system for cross-reactive material-negative factor XI deficiency. Blood (2005) 0.80
The effects of intrinsic pathway protease deficiencies on plasminogen-deficient mice. Blood (2005) 0.80
Factor XI protein in human pancreas and kidney. Thromb Haemost (2008) 0.80
Factor XI/ADAMTS13 complexes are quantitatively insignificant in human plasma. Haematologica (2007) 0.79
Immediate recovery of acquired von Willebrand syndrome after left ventricular assist device explantation: implications for heart transplantation. ASAIO J (2014) 0.79
Functional role of residue 193 (chymotrypsin numbering) in serine proteases: influence of side chain length and beta-branching on the catalytic activity of blood coagulation factor XIa. Biochemistry (2008) 0.79
Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli. Anal Biochem (2010) 0.78
Fine mapping of the H-kininogen binding site in plasma prekallikrein apple domain 2. Int Immunopharmacol (2002) 0.78
Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kininogen. Thromb Haemost (2017) 0.78
Tissue factor and platelet glycoprotein Ib-alpha alleles are associated with age at first coronary bypass operation. Anesthesiology (2003) 0.77
Factor XI antisense oligonucleotide for venous thrombosis. N Engl J Med (2015) 0.77
Single-chain factor XII: a new form of activated factor XII. Curr Opin Hematol (2017) 0.75
Evidence against a protein in plasma that is a product of a factor XI mRNA splice variant missing exons 6 and 7. Blood (2010) 0.75
Acquired factor XI deficiency in a child with membranoproliferative glomerulonephritis. Pediatr Blood Cancer (2011) 0.75
The rebirth of the contact pathway: a new therapeutic target. Curr Opin Hematol (2020) 0.75
Defective binding of factor XI-N248 to activated human platelets. Blood (2007) 0.75